Protara Therapeutics Inc.
TARA | NASDAQ
$3.87
+$0.36 (+10.26%)
Sep 22, 2026, 10:48 AM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | 362K | n/a | 341K | n/a | n/a | 196K |
Gross Profit | -362K | n/a | -341K | n/a | n/a | -196K |
Operating Income | -64.55M | -49.15M | -43.61M | -67.06M | -47.49M | -34.44M |
Interest Income | 6.33M | 4.14M | 2.73M | 1.11M | 237K | 466K |
Pretax Income | -57.44M | -44.6M | -40.42M | -65.95M | -47.25M | -33.98M |
Net Income | -57.44M | -44.6M | -40.42M | -65.95M | -47.25M | -33.98M |
Selling & General & Admin | 21.92M | 17.45M | 18.62M | 20.74M | 26.4M | 22.37M |
Research & Development | 42.63M | 31.7M | 24.79M | 16.81M | 21.09M | 11.88M |
Other Expenses | -362K | n/a | -137K | 29.52M | n/a | n/a |
Operating Expenses | 64.19M | 49.15M | 43.27M | 67.06M | 47.49M | 34.25M |
Interest Expense | n/a | n/a | n/a | 1.14M | 1.74M | 34K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 64.55M | 49.15M | 43.61M | 67.06M | 47.49M | 34.44M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 42.84M | 20.59M | 11.33M | 11.26M | 11.23M | 7.23M |
Shares Outstanding (Diluted) | 42.84M | 20.59M | 11.33M | 11.26M | 11.23M | 7.23M |
EPS (Basic) | -1.34 | -2.17 | -3.57 | -5.86 | -4.20 | -4.70 |
EPS (Diluted) | -1.34 | -2.17 | -3.57 | -5.86 | -4.20 | -4.70 |
EBITDA | -57.08M | -44.26M | -40.08M | -64.57M | -45.4M | -33.78M |
EBIT | -57.44M | -44.6M | -40.42M | -64.82M | -45.52M | -33.98M |
Depreciation & Amortization | 362K | 332K | 341K | 248K | 117K | 196K |
Add to Watchlist
Select watchlists to add or remove TARA